Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer’s Association International Conference 2025
Latest findings from Eisai’s robust Alzheimer’s disease (AD) pipeline include results from lecanemab longterm data, an immunoassay for measuring amyloid-B protofibrils in cerebrospinal fluid, and asubcutaneousl form of lecanemab for continued treatment of AD AD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque deposition […]